Paul J. Hastings - May 15, 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Director
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
May 15, 2023
Transactions value $
-$83,650
Form type
4
Date filed
5/17/2023, 04:07 PM
Previous filing
Jan 18, 2023
Next filing
Jun 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $209K +7K +97.51% $29.90 14.2K May 15, 2023 Direct F1
transaction PCRX Common Stock Sale -$293K -7K -49.37% $41.85 7.18K May 15, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -7K -100% $0.00* 0 May 15, 2023 Common Stock 7K $29.90 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 12, 2013.